Research programme: respiratory disorders therapeutics - Aradigm/CyDex

Drug Profile

Research programme: respiratory disorders therapeutics - Aradigm/CyDex

Alternative Names: ARD 1700

Latest Information Update: 01 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aradigm Corporation; CyDex
  • Developer Aradigm Corporation; CyDex Pharmaceuticals
  • Class Cyclodextrins
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Cholinergic receptor antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 26 Jan 2011 CyDex Pharmaceuticals has been acquired by Ligand Pharmaceuticals
  • 10 Apr 2008 Preclinical development is ongoing
  • 06 Sep 2007 Preclinical trials in Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top